## This Page Is Inserted by IFW Operations and is not a part of the Official Record

## **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

## IMAGES ARE BEST AVAILABLE COPY.

As rescanning documents will not correct images, please do not report the images to the Image Problem Mailbox.

## **IN THE CLAIMS:**

Please amend the claims as follows:

Cancel claims 1-127, without prejudice.

1.-127. (Canceled)

Add new claims 128-203, as follows:

- 128. (New) A method of preventing a respiratory syncytial virus (RSV) infection or a symptom thereof, said method comprising administering to a mammal in need thereof a dose of an effective amount of an antibody comprising a variable light (VL) domain having an amino acid sequence of SEQ ID NO:11, wherein the antibody immunospecifically binds to a RSV antigen and the effective amount results in an effective neutralizing titer of the antibody.
- 129. (New) A method of preventing a RSV infection or a symptom thereof, said method comprising administering to a mammal in need thereof a dose of an effective amount of an antibody comprising a variable heavy (VH) domain having an amino acid sequence of SEQ ID NO:254, wherein the antibody immunospecifically binds to a RSV antigen and the effective amount of the antibody results in an effective neutralizing titer of the antibody.
- 130. (New) The antibody of claim 128 further comprising a VH domain having an amino acid sequence of SEQ ID NO:254.
- 131. (New) A method of preventing a RSV infection or a symptom thereof, said method comprising administering to a mammal in need thereof a dose of an effective amount of an antibody comprising a VH complementarity determining region (CDR) 1 having an amino acid sequence of SEQ ID NO:10, wherein the antibody immunospecifically binds to a RSV antigen and the effective amount of the antibody results in an effective neutralizing titer of the antibody.
- 132. (New) A method of preventing a RSV infection or a symptom thereof, said method comprising administering to a mammal in need thereof a dose of an effective amount of an antibody comprising a VH CDR2 having an amino acid sequence of SEQ ID NO:19, wherein the antibody immunospecifically binds to a RSV antigen and the effective amount of the antibody results in an effective neutralizing titer of the antibody.

- 133. (New) A method of preventing a RSV infection or a symptom thereof, said method comprising administering to a mammal in need thereof a dose of an effective amount of an antibody comprising a VH CDR3 having an amino acid sequence of SEQ ID NO:20, wherein the antibody immunospecifically binds to a RSV antigen and the effective amount of the antibody results in an effective neutralizing titer of the antibody.
- 134. (New) A method of preventing a RSV infection or a symptom thereof, said method comprising administering to a mammal in need thereof a dose of an effective amount of an antibody comprising a VL CDR1 having an amino acid sequence of SEQ ID NO:39, wherein the antibody immunospecifically binds to a RSV antigen and the effective amount of the antibody results in an effective neutralizing titer of the antibody.
- 135. (New) A method of preventing a RSV infection or a symptom thereof, said method comprising administering to a mammal in need thereof a dose of an effective amount of an antibody comprising a VL CDR2 having an amino acid sequence of SEQ ID NO:5, wherein the antibody immunospecifically binds to a RSV antigen and the antibody is not palivizumab, and wherein the effective amount of the antibody results in an effective neutralizing titer of the antibody.
- 136. (New) A method of preventing a RSV infection or a symptom thereof, said method comprising administering to a mammal in need thereof a dose of an effective amount of an antibody comprising a VL CDR3 having an amino acid sequence of SEQ ID NO:6, wherein the antibody immunospecifically binds to a RSV antigen and the antibody is not palivizumab, and wherein the effective amount of the antibody results in an effective neutralizing titer of the antibody.
- 137. (New) The method of claim 131, wherein the antibody further comprises a VL CDR1 having an amino acid sequence of SEQ ID NO:39.
- 138. (New) The method of claim 131, wherein the antibody further comprises a VL CDR2 having an amino acid sequence of SEQ ID NO:5.
- 139. (New) The method of claim 131, wherein the antibody further comprises a VL CDR3 having an amino acid sequence of SEQ ID NO:6.
- 140. (New) The method of claim 132, wherein the antibody further comprises a VL CDR 1 having an amino acid sequence of SEQ ID NO:39.

- 141. (New) The method of claim 132, wherein the antibody further comprises a VL CDR2 having an amino acid sequence of SEQ ID NO:5.
- 142. (New) The method of claim 132, wherein the antibody further comprises a VL CDR3 having an amino acid sequence of SEQ ID NO:6.
- 143. (New) The method of claim 133, wherein the antibody further comprises a VL CDR1 having an amino acid sequence of SEQ ID NO:39.
- 144. (New) The method of claim 133, wherein the antibody further comprises a VL CDR2 having an amino acid sequence of SEQ ID NO:5.
- 145. (New) The method of claim 133, wherein the antibody further comprises a VL CDR3 having an amino acid sequence of SEQ ID NO:6.
- 146. (New) The method of claim 131, wherein the antibody further comprises a VH CDR2 having an amino acid sequence of SEQ ID NO:19.
- 147. (New) The method of claim 131, wherein the antibody further comprises a VH CDR3 having an amino acid sequence of SEQ ID NO:20.
- 148. (New) The method of claim 132, wherein the antibody further comprises a VH CDR3 having an amino acid sequence of SEQ ID NO:20.
- 149. (New) The method of claim 146, wherein the antibody further comprises a VH CDR3 having an amino acid sequence of SEQ ID NO:20.
- 150. (New) The method of claim 146, wherein the antibody further comprises a VL CDR1 having an amino acid sequence of SEQ ID NO:39.
- 151. (New) The method of claim 146, wherein the antibody further comprises a VL CDR2 having an amino acid sequence of SEQ ID NO:5.
- 152. (New) The method of claim 146, wherein the antibody further comprises a VL CDR3 having an amino acid sequence of SEQ ID NO:6.
- 153. (New) The method of claim 147, wherein the antibody further comprises a VL CDR1 having an amino acid sequence of SEQ ID NO:39.
  - 154. (New) The method of claim 147, wherein the antibody further comprises a VL

- CDR2 having an amino acid sequence of SEQ ID NO:5.
- 155. (New) The method of claim 147, wherein the antibody further comprises a VL CDR3 having an amino acid sequence of SEQ ID NO:6.
- 156. (New) The method of claim 148, wherein the antibody further comprises a VL CDR1 having an amino acid sequence of SEQ ID NO:39.
- 157. (New) The method of claim 148, wherein the antibody further comprises a VL CDR2 having an amino acid sequence of SEQ ID NO:5.
- 158. (New) The method of claim 148, wherein the antibody further comprises a VL CDR3 having an amino acid sequence of SEQ ID NO:6.
- 159. (New) The method of claim 149, wherein the antibody further comprises a VL CDR1 having an amino acid sequence of SEQ ID NO:39.
- 160. (New) The method of claim 149, wherein the antibody further comprises a VL CDR2 having an amino acid sequence of SEQ ID NO:5.
- 161. (New) The method of claim 149, wherein the antibody further comprises a VL CDR3 having an amino acid sequence of SEQ ID NO:6.
- 162. (New) The method of claim 134, wherein the antibody further comprises a VL CDR2 having an amino acid sequence of SEQ ID NO:5.
- 163. (New) The method of claim 134, wherein the antibody further comprises a VL CDR3 having an amino acid sequence of SEQ ID NO:5.
- 164. (New) The method of claim 135, wherein the antibody further comprises a VL CDR3 having an amino acid sequence of SEQ ID NO:6.
- 165. (New) The method of claim 162, wherein the antibody further comprises a VL CDR3 having an amino acid sequence of SEQ ID NO:6.
- 166. (New) The method of claim 162, wherein the antibody further comprises a VH CDR1 having an amino acid sequence of SEQ ID NO:10.
- 167. (New) The method of claim 162, wherein the antibody further comprises a VH CDR2 having an amino acid sequence of SEQ ID NO:19.

- 168. (New) The method of claim 162, wherein the antibody further comprises a VH CDR3 having an amino acid sequence of SEQ ID NO:20.
- 169. (New) The method of claim 163, wherein the antibody further comprises a VH CDR1 having an amino acid sequence of SEQ ID NO:10.
- 170. (New) The method of claim 163, wherein the antibody further comprises a VH CDR2 having an amino acid sequence of SEQ ID NO:19.
- 171. (New) The method of claim 163, wherein the antibody further comprises a VH CDR3 having an amino acid sequence of SEQ ID NO:20.
- 172. (New) The method of claim 164, wherein the antibody further comprises a VH CDR1 having an amino acid sequence of SEQ ID NO:10.
- 173. (New) The method of claim 164, wherein the antibody further comprises a VH CDR2 having an amino acid sequence of SEQ ID NO:19.
- 174. (New) The method of claim 164, wherein the antibody further comprises a VH CDR3 having an amino acid sequence of SEQ ID NO:20.
- 175. (New) The method of claim 165, wherein the antibody further comprises a VH CDR1 having an amino acid sequence of SEQ ID NO:10.
- 176. (New) The method of claim 165, wherein the antibody further comprises a VH CDR2 having an amino acid sequence of SEQ ID NO:19.
- 177. (New) The method of claim 165, wherein the antibody further comprises a VH CDR3 having an amino acid sequence of SEQ ID NO:20.
- 178. (New) The method of claim 146, wherein the antibody further comprises a VL CDR1 having an amino acid sequence of SEQ ID NO:39 and a VL CDR2 having an amino acid sequence of SEQ ID NO:5.
- 179. (New) The method of claim 146, wherein the antibody further comprises a VL CDR1 having an amino acid sequence of SEQ ID NO:39 and a VL CDR3 having an amino acid sequence of SEQ ID NO:6.
- 180. (New) The method of claim 146, wherein the antibody further comprises a VL CDR2 having an amino acid sequence of SEQ ID NO:5 and a VL CDR3 having an amino

acid sequence of SEQ ID NO:6.

- 181. (New) The method of claim 146, wherein the antibody further comprises a VL CDR1 having an amino acid sequence of SEQ ID NO:39, a VL CDR2 having an amino acid sequence of SEQ ID NO:5, and a VL CDR3 having an amino acid sequence of SEQ ID NO:6.
- 182. (New) The method of claim 147, wherein the antibody further comprises a VL CDR1 having an amino acid sequence of SEQ ID NO:39 and a VL CDR2 having an amino acid sequence of SEQ ID NO:5.
- 183. (New) The method of claim 147, wherein the antibody further comprises a VL CDR1 having an amino acid sequence of SEQ ID NO:39 and a VL CDR3 having an amino acid sequence of SEQ ID NO:6.
- 184. (New) The method of claim 147, wherein the antibody further comprises a VL CDR2 having an amino acid sequence of SEQ ID NO:5 and a VL CDR3 having an amino acid sequence of SEQ ID NO:6.
- 185. (New) The method of claim 147, wherein the antibody further comprises a VL CDR1 having an amino acid sequence of SEQ ID NO:39, a VL CDR2 having an amino acid sequence of SEQ ID NO:5, and a VL CDR3 having an amino acid sequence of SEQ ID NO:6.
- 186. (New) The method of claim 148, wherein the antibody further comprises a VL CDR1 having an amino acid sequence of SEQ ID NO:39 and a VL CDR2 having an amino acid sequence of SEQ ID NO:5.
- 187. (New) The method of claim 148, wherein the antibody further comprises a VL CDR1 having an amino acid sequence of SEQ ID NO:39 and a VL CDR3 having an amino acid sequence of SEQ ID NO:6.
- 188. (New) The method of claim 148, wherein the antibody further comprises a VL CDR2 having an amino acid sequence of SEQ ID NO:5 and a VL CDR3 having an amino acid sequence of SEQ ID NO:6.
- 189. (New) The method of claim 148, wherein the antibody further comprises a VL CDR1 having an amino acid sequence of SEQ ID NO:39, a VL CDR2 having an amino acid

sequence of SEQ ID NO:5, and a VL CDR3 having an amino acid sequence of SEQ ID NO:6.

- 190. (New) The method of claim 149, wherein the antibody further comprises a VL CDR1 having an amino acid sequence of SEQ ID NO:39 and a VL CDR2 having an amino acid sequence of SEQ ID NO:5.
- 191. (New) The method of claim 149, wherein the antibody further comprises a VL CDR1 having an amino acid sequence of SEQ ID NO:39 and a VL CDR3 having an amino acid sequence of SEQ ID NO:6.
- 192. (New) The method of claim 149, wherein the antibody further comprises a VL CDR2 having an amino acid sequence of SEQ ID NO:5 and a VL CDR3 having an amino acid sequence of SEQ ID NO:6.
- 193. (New) The method of claim 149, wherein the antibody further comprises a VL CDR1 having an amino acid sequence of SEQ ID NO:39, a VL CDR2 having an amino acid sequence of SEQ ID NO:5, and a VL CDR3 having an amino acid sequence of SEQ ID NO:6.
- 194. (New) The method of any one of claims 128, 129, 130 or 131-134, wherein the effective amount is 15 mg/kg or less, 10 mg/kg or less, 5 mg/kg or less or 3 mg/kg or less or 1.5 mg/kg or less.
- 195. (New) The method of any one of claims 128, 129, 130 or 131-134, wherein the effective neutralizing titer is at least 1  $\mu$ g/ml, at least 2  $\mu$ g/ml, at least 4  $\mu$ g/ml, at least 6  $\mu$ g/ml, at least 30  $\mu$ g/ml, 35  $\mu$ g/ml, at least 40  $\mu$ g/ml, at least 50  $\mu$ g/ml, at least 75  $\mu$ g/ml, at least 100  $\mu$ g/ml, at least 150  $\mu$ g/ml or at least 200  $\mu$ g/ml.
- 196. (New) The method of any one of claims 128, 129, 130 or 131-134, wherein the effective neutralizing titer is maintained for at least 20 days, at least 25 days or at least 30 days after administration of the dose.
- 197. (New) The method of any one of claims 128, 129, 130 or 131-134, wherein the antibody is administered by a nebulizer or inhaler.
- 198. (New) The method of any one of claims 128, 129, 130 or 131-134, wherein the antibody is administered intramusclarly, intravenously or subcutaneously.

- 199. (New) The method of any one of claims 128, 129, 130 or 131-134, wherein the antibody is a monoclonal antibody, a human antibody, a humanized antibody, a multispecific antibody, a chimeric antibody, a Fab fragment, a single-chain Fv or a single chain antibody.
- 200. (New) The method of any one of claims 128, 129, 130 or 131-134, wherein the antibody is administered 1, 2, 3, 4 or 5 times during the RSV season.
- 201. (New) The method of any one of claims 128, 129, 130 or 131-134, wherein the mammal is a human subject.
- 202. (New) The method of claim 201, wherein the human subject is a human infant, a human infant born prematurely or at risk of hospitalization for a RSV infection, a human subject which has had a bone marrow transplant, an elderly human subject, or a human subject which has cystic fibrosis, bronchopulmonary dysplasia, congenital heart disease, congenital immunodeficiency or acquired immunodeficiency.
- 203. (New) The method of any one of claims 128, 129, 130 or 131-134 further comprising administering to the mammal hormonal therapy, immunotherapy or an anti-inflammatory agent.